Suven Life Sciences Ltd (Suven) announces today that the grant of one (1) product patent from New Zealand (728918) and one (1) product patent from Sri Lanka (17300) corresponding to the New Chemical Entity for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2034 and 2031 respectively.
The granted claims of the patents include the class of selective 5-HT4 and H3 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.
Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.306.5 as compared to the previous close of Rs. 309.1. The total number of shares traded during the day was 269894 in over 5413 trades.
The stock hit an intraday high of Rs. 315 and intraday low of 298.7. The net turnover during the day was Rs. 82896566.